Evidence map›Paper›PMID 29456245›Full record

ReviewNature reviews. Nephrology2018

Animal models of monoclonal immunoglobulin-related renal diseases.

Christophe Sirac, Guillermo A Herrera, Paul W Sanders, Vecihi Batuman, Sebastien Bender, Maria V Ayala, Vincent Javaugue, Jiamin Teng, Elba A Turbat-Herrera, Michel Cogné and 3 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Renal manifestations of MGUS.Hematology. American Society of Hematology. Education Program · 2024
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

Christophe SiracCNRS UMR 7276-CRIBL, University of Limoges, Limoges, France, and French National Reference Centre for "AL Amyloidosis and Other Monoclonal Immunoglobulin Deposition Diseases", University Hospital Dupuytren, Limoges, France.
Guillermo A HerreraDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center, Shreveport, LA, USA.
Paul W SandersDivision of Nephrology, Department of Medicine, University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center, Birmingham, AL, USA.
Vecihi BatumanDepartment of Medicine, Southeast Louisiana Veterans Health Care System, New Orleans, LA, USA, and Department of Medicine, Nephrology Section-SL45, Tulane University Medical School, New Orleans, LA, USA.
Sebastien BenderCNRS UMR 7276-CRIBL, University of Limoges, Limoges, France, and French National Reference Centre for "AL Amyloidosis and Other Monoclonal Immunoglobulin Deposition Diseases", University Hospital Dupuytren, Limoges, France.
Maria V AyalaCNRS UMR 7276-CRIBL, University of Limoges, Limoges, France, and French National Reference Centre for "AL Amyloidosis and Other Monoclonal Immunoglobulin Deposition Diseases", University Hospital Dupuytren, Limoges, France.
Vincent JavaugueCNRS UMR 7276-CRIBL, University of Limoges, Limoges, France, and French National Reference Centre for "AL Amyloidosis and Other Monoclonal Immunoglobulin Deposition Diseases", University Hospital Dupuytren, Limoges, France.
Jiamin TengDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center, Shreveport, LA, USA.
Elba A Turbat-HerreraDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center, Shreveport, LA, USA.
Michel CognéCNRS UMR 7276-CRIBL, University of Limoges, Limoges, France, and French National Reference Centre for "AL Amyloidosis and Other Monoclonal Immunoglobulin Deposition Diseases", University Hospital Dupuytren, Limoges, France.
Guy TouchardDepartment of Nephrology and Transplantation, University Hospital of Poitiers, Poitiers, France.
Nelson LeungDivision of Nephrology and Hypertension and Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Frank BridouxCNRS UMR 7276-CRIBL, University of Limoges, Limoges, France, and French National Reference Centre for "AL Amyloidosis and Other Monoclonal Immunoglobulin Deposition Diseases", University Hospital Dupuytren, Limoges, France.
Louisiana State University Health Sciences Center Shreveport · USUniversité de Poitiers · FRUniversité de Limoges · FRContrôle de la Réponse Immune B et Lymphoproliférations · FRMayo Clinic · USSoutheast Louisiana Veterans Health Care System · USUniversity of Alabama at Birmingham · US

Funding

UAB-UCSD O'Brien Core Center for Acute Kidney Injury ResearchP30DK079337 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AGARWAL, ANUPAM · 2008 to 2022
$18.3M
BLRD VA I01 BX001192CSRD VA I01 CX001326NIDDK NIH HHS P30 DK079337
6 · The paper itself

Abstract

The renal deposition of monoclonal immunoglobulins can cause severe renal complications in patients with B cell and plasma cell lymphoproliferative disorders. The overproduction of a structurally unique immunoglobulin can contribute to the abnormal propensity of monoclonal immunoglobulins to aggregate and deposit in specific organs. A wide range of renal diseases can occur in multiple myeloma or monoclonal gammopathy of renal significance, including tubular and glomerular disorders with organized or unorganized immunoglobulin deposits. The development of reliable experimental models is challenging owing to the inherent variability of immunoglobulins and the heterogeneity of the pathologies they produce. However, although imperfect, animal models are invaluable tools to understand the molecular pathogenesis of these diseases, and advances in creating genetically modified animals might provide novel approaches to evaluate innovative therapeutic interventions. We discuss the strategies employed to reproduce human monoclonal immunoglobulin-induced kidney lesions in animal models, and we highlight their advantages and shortcomings. We also discuss how these models have affected the management of these deposition diseases and might do so in the future. Finally, we discuss hypotheses that explain some limitations of the various models, and how these models might improve our understanding of other nephropathies without immunoglobulin involvement that have similar pathogenic mechanisms.

Indexed as

Disease Models, AnimalAnimalsAntibodies, MonoclonalImmunoglobulinsKidney DiseasesMice, TransgenicParaproteinemiasAntibodies, MonoclonalImmunoglobulins

Identifiers

PMID29456245
OpenAlexW2788178893

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.